Thresholds for advanced fibrosis and cirrhosis

*]:pointer-events-auto [content-visibility:auto] supports-[content-visibility:auto]:[contain-intrinsic-size:auto_100lvh] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" tabindex="-1" data-turn-id= "request-WEB:e5fd8283-e54f-448f-b002-d3203624b2a4-0" data-testid= "conversation-turn-2" data-scroll-anchor="true" data-turn= "assistant">

Dr. Venkata Katabathina breaks down the newly adopted MASLD nomenclature and its implications for diagnosing and managing metabolic dysfunction–associated steatotic liver disease. He highlights updated AASLD guidelines, the expanding role of advanced imaging, and how radiologists are central to early detection, treatment selection, and longitudinal disease monitoring.

Current Update on Nomenclature, Diagnosis,and Management of Metabolic Dysfunction–associated Steatotic Liver Disease:Radiologists' Perspective. Osta et al. RadioGraphics 2025; 45(12):e240221.